Please assess the completion status of the following clinical trial:

Trial Title: PLASOMA Efficacy & Technology Health (PETH) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~INCL1: have a slow-healing or non-healing lower leg ulcer presumed to be caused by venous insufficiency (VLU). The wound should have insufficient healing (\<30% surface area reduction) during the last 2 weeks of standard wound care.~INCL2: have a wound with a minimum wound surface area of 0.5 cm2 and a maximum diameter of 6 cm (\~28 cm2 wound surface area for circular wounds).~INCL3: have an Ankle Brachial Pressure Index (ABPI) between 0.8 and 1.3. Note 1: subject can be included based on a VLU diagnosis from anamnesis. Make sure an ABPI measurement is performed as soon as possible to verify the diagnosis. The subject has to be excluded if the ABPI is not between 0.8 and 1.3.~Note 2: For diabetic patients an ABPI measurement is not always reliable. Therefore, diabetic patients can be included based on a VLU diagnosis from anamnesis, but no ABPI measurement needs to be performed.~INCL4: have a minimum age of 18 years old.~INCL5: For home care treatments only: there is a grounded wall socket available for connection of PLASOMA.~Exclusion Criteria:~EXCL1: the subject has one or more of the following contraindications for PLASOMA:~* the wound is very exudative, i.e. wounds in which moisture is visible again within a few minutes after patting dry.~* any implanted active electronic device, such as a pacemaker, is present.~* an electronic medical device is attached to the body, including electronic life support equipment, hearing aids, glucose sensors and insulin pumps. If the sole purpose of the medical device is monitoring, the subject is not excluded, but it should be noted that use of PLASOMA together with such devices has not been tested and may lead to erroneous operation of the attached device during PLASOMA treatment.~Note: no exclusion if electronic medical device will be detached during PLASOMA treatment.~* a metal implant (including a stent) is present in the treatment area, i.e. the area between pad and electrode.~* a conductive connection from outside to inside the body at or near the heart is present, e.g. a catheter with electrolyte fluid.~* the subject has epilepsy~* the subject is pregnant~EXCL2: the subject uses systemic antibiotics.~EXCL3: the subject has any known malignant wound degeneration.~EXCL4: the subject receives treatment with immunosuppressive agents or oral corticosteroids; no exclusion if subject has received a stable dose for at least 2 months and the oral corticosteroid dose does not exceed 7.5 mg/day prednisone or equivalent.~EXCL5: the subject is receiving or likely to receive advanced wound dressings or advanced therapies- such as negative pressure therapy, hyperbaric oxygen therapy, biologicals (e.g. skin substitutes, growth factors), electrophysical therapy - for the to-be-treated wound.~EXCL6: the subject cannot (agree to) comply with the SOC.~EXCL7: the subject participates in another study which is likely to compromise the outcome of the PETH study or the feasibility of thesubject fulfilling the PETH study.~EXCL8: the subject is unable to provide consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): None
- 1x PLASOMA (Type: EXPERIMENTAL): None
- 2x PLASOMA (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).